Thermo Fisher shareholders reject say-on-pay at annual meeting
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Thermo Fisher ( (TMO) ) has shared an update.
At Thermo Fisher Scientific’s annual meeting on May 20, 2026, shareholders elected all nominated directors to one-year terms expiring at the 2027 meeting, reaffirming the existing board slate despite varying vote margins across individual nominees. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent auditor for the 2026 fiscal year, but notably failed to approve the advisory resolution on executive compensation, signaling investor dissatisfaction with pay practices that could pressure the board’s compensation oversight and future pay design.
The rejection of the say-on-pay proposal contrasts with the otherwise strong support for board nominees and auditor ratification, highlighting a targeted concern around named executive officer compensation rather than broader governance structure. This outcome may prompt Thermo Fisher’s leadership to engage more closely with investors on remuneration policies and adjust compensation frameworks to address shareholder expectations while maintaining continuity in audit oversight and board leadership.
The most recent analyst rating on (TMO) stock is a Buy with a $625.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.
Spark’s Take on TMO Stock
According to Spark, TipRanks’ AI Analyst, TMO is a Neutral.
The score is driven primarily by solid fundamentals—strong margins and free-cash-flow generation—plus supportive raised full-year guidance. These positives are tempered by a weak technical trend (price below major moving averages), premium valuation with low yield, and elevated leverage alongside only modest organic growth.
To see Spark’s full report on TMO stock, click here.
More about Thermo Fisher
Thermo Fisher Scientific is a life sciences and laboratory equipment company that provides analytical instruments, laboratory products, diagnostic tools and related services to pharmaceutical, biotechnology, academic and industrial customers worldwide. The company focuses on enabling scientific research, clinical diagnostics and applied markets with integrated technologies and services.
Average Trading Volume: 2,178,571
Technical Sentiment Signal: Sell
Current Market Cap: $166.6B
See more insights into TMO stock on TipRanks’ Stock Analysis page.
